Abstract
Botulinum neurotoxins (BoNTs), the most potent known toxins, cause severe muscle paralysis and death at nanogram exposures and are considered biothreat agents. BoNTs target the neuromuscular junction where they release smaller zinc metalloprotease light chains (LCs) into the neuron cytosol that selectively cleave SNARE proteins and thus block the exocytosis of acetylcholine neurotransmitters necessary for skeletal muscle contraction. The majority of efforts to develop post-symptomatic therapeutics for botulism poisoning have focused on inhibiting the LC and tremendous strides have been made in understanding how the LC binds to the SNARE proteins via X-ray crystallography. Subsequent homology modeling and structure based drug design have led to the discovery of multiple small molecule BoNT/A inhibitors in the 0.05 ~10 μΜ range, but to date none have shown significant post-symptomatic efficacy in an animal model of botulinum intoxication. With the lack of reported pharmacokinetic data, we have analyzed the BoNT/A inhibitor lead chemical matter from a physicochemical property point of view and have attempted to understand if bioavailability of drug at the neuromuscular junction is the root cause of this apparent in vitro/in vivo disconnect in the field.
Keywords: Botulinum neurotoxin, Botulism, Drug discovery, Botulinum inhibitors, Protease inhibitors, SNAP-25.
Current Topics in Medicinal Chemistry
Title:Searching for Therapeutics Against Botulinum Neurotoxins: A True Challenge for Drug Discovery
Volume: 16 Issue: 21
Author(s): Allen J. Duplantier, Christopher D. Kane and Sina Bavari
Affiliation:
Keywords: Botulinum neurotoxin, Botulism, Drug discovery, Botulinum inhibitors, Protease inhibitors, SNAP-25.
Abstract: Botulinum neurotoxins (BoNTs), the most potent known toxins, cause severe muscle paralysis and death at nanogram exposures and are considered biothreat agents. BoNTs target the neuromuscular junction where they release smaller zinc metalloprotease light chains (LCs) into the neuron cytosol that selectively cleave SNARE proteins and thus block the exocytosis of acetylcholine neurotransmitters necessary for skeletal muscle contraction. The majority of efforts to develop post-symptomatic therapeutics for botulism poisoning have focused on inhibiting the LC and tremendous strides have been made in understanding how the LC binds to the SNARE proteins via X-ray crystallography. Subsequent homology modeling and structure based drug design have led to the discovery of multiple small molecule BoNT/A inhibitors in the 0.05 ~10 μΜ range, but to date none have shown significant post-symptomatic efficacy in an animal model of botulinum intoxication. With the lack of reported pharmacokinetic data, we have analyzed the BoNT/A inhibitor lead chemical matter from a physicochemical property point of view and have attempted to understand if bioavailability of drug at the neuromuscular junction is the root cause of this apparent in vitro/in vivo disconnect in the field.
Export Options
About this article
Cite this article as:
Duplantier J. Allen, Kane D. Christopher and Bavari Sina, Searching for Therapeutics Against Botulinum Neurotoxins: A True Challenge for Drug Discovery, Current Topics in Medicinal Chemistry 2016; 16 (21) . https://dx.doi.org/10.2174/1568026616666160413135630
DOI https://dx.doi.org/10.2174/1568026616666160413135630 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Molecular Basis for the Mode of Action of Bicyclomycin
Current Drug Targets - Infectious Disorders The Role of the Oxysterol/EBI2 Pathway in the Immune and Central Nervous Systems
Current Drug Targets Involvement of Cytochromes P450 2D6, 2B6 and 2C19 in the Metabolism of (-)-Deprenyl and N-Methyl,N-propargylphenylethylamine
Drug Metabolism Letters Flow Chemistry to Control the Synthesis of Nano and Microparticles for Biomedical Applications
Current Topics in Medicinal Chemistry Proteome Adjustments Post Gradual Hypoxic Stress in Barilius bendelisis: Insights into Adaptive Strategies of a Hill Stream Cyprinid
Current Proteomics Aldose Reductase Enzyme and its Implication to Major Health Problems of the 21st Century
Current Medicinal Chemistry Enoyl Reductases as Targets for the Development of Anti-Tubercular and Anti-Malarial Agents
Current Drug Targets Targeting Allosteric Control Mechanisms in Heat Shock Protein 70 (Hsp70)
Current Topics in Medicinal Chemistry Arterial Spin Labeling Perfusion MRI in Alzheimers Disease
Current Medical Imaging The Protein Kinase Inhibitor Balanol: Structure – Activity Relationships and Structure-Based Computational Studies
Anti-Cancer Agents in Medicinal Chemistry Autism: Pathophysiology and Promising Herbal Remedies
Current Pharmaceutical Design From Axonal Transport to Mitochondrial Trafficking: What Can We Learn from Manganese-Enhanced MRI Studies in Mouse Models of Alzheimers Disease?
Current Medical Imaging Life Under Stress: The Probiotic Stress Response and How it may be Manipulated
Current Pharmaceutical Design Editorial: The Art and Science of Adolescent Psychiatry and Psychology
Adolescent Psychiatry Recents Patents for Isolating, Delivering and Tracking Adult Stem Cells in Regenerative Medicine
Recent Patents on Drug Delivery & Formulation Molecular Recognition of Cyclic-Nucleotides and Current Sensors for Their Detection
Current Protein & Peptide Science New Perspectives in the Management of Post-Surgical Macular Edema
Recent Patents on Drug Delivery & Formulation Delivery of Peptides Via the Oral Route: Diabetes Treatment by Peptide-Loaded Nanoparticles
Current Pharmaceutical Design Breast Cancer: Current Developments in Molecular Approaches to Diagnosis and Treatment
Recent Patents on Anti-Cancer Drug Discovery Small Conductance Ca2+-Activated K+ Channels as Targets of CNS Drug Development
Current Drug Targets - CNS & Neurological Disorders